S-1416 : Still Just a Bill


Affordable Prescriptions for Patients Act of 2019

This bill prohibits patent thicketing and product hopping by drug manufacturers. In general, patent thicketing occurs when a drug manufacturer obtains new patents related to a previously-patented drug, biological product, or underlying chemical composition that extends the manufacturer’s market exclusivity for that drug without demonstrating that the new patents serve a meaningful purpose other than limiting competition from generic drug manufacturers.

Product hopping is presumed when a drug manufacturer obtains removal of a drug from the Food and Drug Administration’s approved drug list, discontinues a drug, or markets a reformulation of an already-approved drug during a certain period after which the manufacturer has been notified that a competing drug manufacturer has applied for generic drug approval. These practices are not considered product hopping if the manufacturer demonstrates that the drug was removed from the approved-drug list for safety reasons. Or, in the case of a drug reformulation, the manufacturer shows that the modified product provides a significant health benefit, is the option least likely to reduce competition, and is based on substantial financial considerations unrelated to limiting competition.

The Federal Trade Commission may penalize violating manufacturers and bring claims in federal court to prohibit the conduct and provide restitution.

Action Timeline

Action DateTypeTextSource
2019-06-28CalendarsPlaced on Senate Legislative Calendar under General Orders. Calendar No. 132.Senate
2019-06-28CommitteeCommittee on the Judiciary. Reported by Senator Graham with an amendment in the nature of a substitute. Without written report.Senate
2019-06-27CommitteeCommittee on the Judiciary. Ordered to be reported with an amendment in the nature of a substitute favorably.Senate
2019-05-09IntroReferralRead twice and referred to the Committee on the Judiciary.Senate
2019-05-09IntroReferralIntroduced in SenateLibrary of Congress

Policy Area :

Commerce
Related Subjects
  • Administrative remedies
  • Civil actions and liability
  • Competition and antitrust
  • Consumer affairs
  • Drug safety, medical device, and laboratory regulation
  • Health care costs and insurance
  • Inflation and prices
  • Intellectual property
  • Judicial review and appeals
  • Manufacturing
  • Prescription drugs
Related Geographic Entities
Related Organizations
  • Federal Trade Commission (FTC)

Related Bills

See Related Bills